Agios Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 386
- Market Cap
- $2.6B
- Website
- http://www.agios.com
- Introduction
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is...
Tebapivat Scores FDA Orphan Drug Designation in MDS-Associated Anemia
Tebapivat, a novel PK activator, received orphan drug designation from the FDA for treating anemia in lower-risk MDS. A phase 2b study is evaluating tebapivat, aiming for transfusion independence in anemia-affected MDS patients.
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for ...
Agios Pharmaceuticals announced FDA orphan drug designation for its PK activator tebapivat in treating myelodysplastic syndromes (MDS). The designation supports development for rare disorders affecting fewer than 200,000 people in the U.S., offering incentives like tax credits and potential market exclusivity. Agios aims to deliver the first oral therapy addressing anemia in lower-risk MDS, currently in Phase 2b study.
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treating Myelodysplastic Syndromes (MDS)
Agios Pharmaceuticals announced FDA orphan drug designation for tebapivat, its PK activator, for treating myelodysplastic syndromes (MDS). The designation aims to provide new oral treatment options for MDS patients, affecting 75,000-80,000 in the U.S. and EU5. Agios completed a Phase 2a study and is initiating a Phase 2b study for tebapivat in lower-risk MDS.
© Copyright 2024. All Rights Reserved by MedPath